default author photo

Tizita Zeleke

Icahn School of Medicine at Mount Sinai Hospital - Graduate School

One Gustave L. Levy Place

New York, NY 10029-6574

United States

  • Icahn School of Medicine at Mount Sinai Hospital - Graduate School

SCHOLARLY PAPERS

1

DOWNLOADS

40

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Network-Based Assessment of HDAC6 Activity is Highly Predictive of Pre-Clinical and Clinical Responses to the HDAC6 Inhibitor Ricolinostat

Number of pages: 45 Posted: 15 Oct 2020
Tizita Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna Trivedi, Melissa Accordino, Katherine Crew, Dawn Hershman, Matthew Maurer, Simon Jones, Andrea Califano, Kevin Kalinsky, Jiyang Yu and Jose Silva
Icahn School of Medicine at Mount Sinai Hospital - Graduate School, St. Jude Children’s Research Hospital - Department of Computational Biology, Columbia University - Department of Medicine, Genentech, Inc. - San Francisco, DarwinHealth, Inc., Columbia University - Department of Medicine, Acetylon Pharmaceuticals, Icahn School of Medicine at Mount Sinai Hospital - Graduate School, Icahn School of Medicine at Mount Sinai Hospital - Graduate School, Columbia University - Department of Medicine, Columbia University - Department of Medicine, Columbia University - Department of Medicine, Columbia University - Department of Medicine, Columbia University - Herbert Irving Comprehensive Cancer Center, Columbia University - Department of Medicine, Columbia University - Department of Medicine, Bristol Myers Squibb, Regenacy Pharmaceuticals Inc., Columbia University Irving Medical Center - Department of Systems Biology, Columbia University - Department of Medicine, St. Jude Children’s Research Hospital - Department of Computational Biology and Mount Sinai Health System - Department of Oncological Sciences
Downloads 40 (1,183,237)

Abstract:

Loading...

Breast Cancer, ricolinostat, HDAC6, clinical trial, biomarker, c-MYC